However, even with these 2 cohorts excluded, the frequency of ERCC2 mutations in the neoadjuvant cases summarized in Supplemental Figure 1B may still be higher than in a nonselected MIBC population because patients in the DFCI-MSKCC and Philadelphia cohorts were specifically included in the cohorts based on tumor response to cisplatin-based therapy. This evidence concerns the gene ERCC2 and neoplasm.